In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gemini Genomics AB

Division of Sequenom Inc.

Latest From Gemini Genomics AB

Pharmacogenomics' Reality Check

Pharmacogenomics is making its way into the infrastructure of clinical medicine. Large companies are discussing pharmacogenomics at the board level, and issuing top-down pronouncements about it. It is also entering the vocabulary of drug testing teams; pharmacogenomics is, for instance, being applied to traditional pharmacogenetic drug metabolism tests. The technology will almost certainly impact drug discovery. Knowing the genetic variability of a target can help a drug developer choose the best candidate from among three or four leads early in the game. But cost-effective enabling technologies do not yet exist. Most sorely missed are cost-effective, high-throughput genotyping methods. For now, companies are banking samples of patients' DNA and developing genetic tests to accompany drugs in clinical trials and on the market. Even as tool providers work to overcome technology hurdles, drug companies unquestionably remain worried about the possibility that pharmacogenomics information could limit the market potential of their products. Nevertheless, the buy-in may well come--surprisingly--from marketing people.
BioPharmaceutical Platform Technologies

Chutzpah: Millennium Takes on Diagnostics

Millennium is turning its business development skills on diagnostics, promising to create a high margin business in what has been a price-cutter's paradise. Its advantage: using the discovery infrastructure built at Millennium and financed by drug companies for their deals with Millennium on drug discovery. All Millennium claims that it needs to make diagnostics pay (it hasn't for the vast majority of other diagnostics start-ups) is funding from diagnostics companies and drug firms interested in pursuing pharmacogenomics. Its major competition, the joint venture between SmithKline and Incyte called diaDexus, is skeptical that diagnostic firms, which have hitherto spent their R&D budgets on developing new instrument platforms, not the high risk hunt for new diagnostic markers, will change their tune now, and spend more on biological research than they ever have before by signing deals with Millennium. But Millennium is convinced that without the kind of new, important and expensive diagnostics it can discover with its biotech platform, such traditional diagnostic firms will continue to merely grind their profitability down in price wars.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Eurona Medical AB
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Sequenom Inc.
  • Senior Management
  • Per H.R. Lindstrom, Chmn., Pres. & CEO
    Lars Wahlstedt, CFO
    Tommy Lewander, PhD, VP, R&D
    Torbjorn Norberg, CTO
    Thomas Pollare, MD, PhD, VP, Bus. Dev.
  • Contact Info
  • Gemini Genomics AB
    Phone: (46) 18480450
    Kungsangsvagen 29, Box 398
    S-751 06